Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ IL-13 Monoclonal Antibody (38213)

Rat Monoclonal Antibody
Supplier: Invitrogen™ MA523735
Description
In ELISAs, this antibody shows less than 0.1% cross-reactivity with recombinant human IL-13. Reconstitute at 0.5 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 μg of the antibody by the LAL method.
IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 cells, and is involved in regulating inflammatory and immune responses. IL-13 down-regulates macrophage activity, thereby inhibiting the production of pro-inflammatory cytokines and chemokines, and is involved in allergen-induced asthma through mechanisms independent of IgE and eosinophils. IL-13 also regulates several stages of B cell maturation and differentiation, up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. Structurally, IL-13 closely resembles IL-3, IL-4, IL-5 and GM-CSF. The gene encoding IL-13, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with the IL-13 gene particularly close to IL4.
Specifications
IL-13 | |
Monoclonal | |
0.5 mg/mL | |
PBS with 5% trehalose and No Preservative | |
P20109 | |
Il13 | |
E. coli-derived recombinant mouse IL-13. | |
500 μg | |
Primary | |
Mouse | |
Antibody | |
IgG2a |
ELISA, Neutralization, Western Blot | |
38213 | |
Unconjugated | |
Il13 | |
ALRH; ALRH antibody; BHR1; il 13; Il13; Il-13; IL-13; cytokine; ILN; Interleukin; interleukin 13; Interleukin13; interleukin-13; interleukin-13 precursor; L13; MGC116786; MGC116788; MGC116789; NC30; NC30 antibody; P600; P600 antibody; T-cell activation protein P600 | |
Rat | |
Protein A/G | |
RUO | |
16163 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction